Vicki Moore, PhD

Contributing Writer https://www.pulmonologyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

General Pulmonology

Risk of Second Cancer Lower With FOLFOX Than With FULFOL

Vicki Moore, PhD

August 9, 2022

Overall, adjuvant chemotherapy does not appear to increase the risk of second cancers for patients with stage III-IV colon cancer.

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

Lung Cancer

Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation

Vicki Moore, PhD

July 5, 2022

Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.

Lung Cancer

Disparities in Lung Cancer Screening Hidden by Aggregation of Ethnic Groups in Hawaii

Vicki Moore, PhD

February 11, 2022

A study identified lung cancer screening completion rates among racial/ethnic groups in Hawaii and found evidence of possible, nonsignificant disparities.

General Medicine

Complications in Patients With Sickle Cell Disease Following ChAdOx1 nCov-19 Vaccination

Vicki Moore, PhD

November 11, 2021

Researchers sought to describe cases of 3 patients with SCD who had a severe vaso-occlusive crisis after receiving the ChAdOx1 nCov-19 vaccine.

Lung Cancer

Smoking Cessation Improves Survival Outcomes for Patients With Non-Small Cell Lung Cancer

Vicki Moore, PhD

September 17, 2021

Researchers found links between smoking cessation and survival outcomes among patients who were smokers at the time of non-small cell lung cancer diagnosis.

Targeted and immunotherapies appear to be opening a new frontier in the management of elderly patien

Lung Cancer

Fatigue as a Mortality Predictor in Advanced Cancer

Vicki Moore, PhD

September 14, 2021

Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.

Lung Cancer

Baseline Fatigue as a Predictor of Mortality Outcomes in Prostate and Lung Cancer

Vicki Moore, PhD

August 26, 2021

Clinically significant fatigue at baseline was identified as a predictive factor for mortality in studies of 2 forms of cancer treated with chemotherapy.